Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study

Incidence of secondary bacterial infections following utilization of tocilizumab for the treatment of COVID-19 – A matched retrospective cohort study

Introduction: Immunosuppressive agents are theorized to target the cytokine storm syndrome in COVID-19. However, the downstream effects regarding susceptibilities to secondary infection risk remains unknown. This study seeks to determine risk differences for secondary infections among COVID-19 patie...

Full description

Bibliographic Details
Main Authors: Joanna L Moore, Stephanie J Stroever, Patricia E Rondain, Robyn N Scatena
Format: Article
Language:English
Published: Wolters Kluwer Medknow Publications 2021-01-01
Series:Journal of Global Infectious Diseases
Subjects:
coronavirus
covid-19
il-6
sars-cov-2
secondary infection
tocilizumab
Online Access:http://www.jgid.org/article.asp?issn=0974-777X;year=2021;volume=13;issue=2;spage=67;epage=71;aulast=Moore

Internet

http://www.jgid.org/article.asp?issn=0974-777X;year=2021;volume=13;issue=2;spage=67;epage=71;aulast=Moore

Similar Items